VivaVision Biotech
PrivateLast Round
Series D+
Nov 1, 2025
Est. Valuation
$257.37M
Total Funding Raised
$131.09M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
VivaVision Biotech is a clinical-stage pharmaceutical company that develops best-in-class and first-in-class therapies for ocular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VivaVision Biotech Comparables
Compare VivaVision Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRIM Biotechnology, Inc. | 81% | |
| Arctic Vision | 80% | |
| Ocumension Therapeutics | 80% |
VivaVision Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D+ | Nov 1, 2025 | ||||
| Grant | Jan 5, 2024 | ||||
| Series D Extension | May 6, 2023 | ||||
| Series D Extension | Apr 1, 2023 | ||||
| Series D | Apr 19, 2021 | ||||
Series C | Nov 1, 2019 |
VivaVision Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| V-Capital | Series D Extension |
| Lapam Capital | Series D, Series B |
| Cenova Capital | Series D |
| Viva Biotech | Series B, Series A Extension, Series D |
| Innovation and Technology Commission | Grant |
| JMCR Partners | Series D, Series C |
| Shenzhen GTJA Investment Group | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 133% MoM.
- Mar 3, 2026
Monthly visitors increased 54% MoM.
VivaVision Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about VivaVision Biotech's valuation, stock price, and market status.
Is VivaVision Biotech a public or private company?
VivaVision Biotech is a private company.
What is the current stock price of VivaVision Biotech?
VivaVision Biotech is a private company with no public stock price. No recent secondary market data is available.
How much is VivaVision Biotech worth (valuation)?
Valuation information for VivaVision Biotech is not publicly available.
Can I buy VivaVision Biotech stock?
VivaVision Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was VivaVision Biotech's last funding round?
VivaVision Biotech's most recent funding round was Series D Extension on May 6, 2023.
Who are the main investors in VivaVision Biotech?
Key investors in VivaVision Biotech include V-Capital, HongShan.
Will VivaVision Biotech IPO soon?
No public IPO plans have been announced for VivaVision Biotech.
How can I track VivaVision Biotech secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VivaVision Biotech's secondary market activity and sign up for updates.